 |
|
|
| |
Pooled Week-48 Analysis of HIV-1 Drug Resistance in E/C/F/TAF (Genvoya) Phase 3 Studies
|
| |
| |
Reported by Jules Levin
CROI 2016 Feb 22-24 Boston
Michael E. Abram, Nicolas A. Margot, Stephanie W. Cox, Renee R. Ram, Danielle P. Porter, Kathryn M. Kitrinos, Marshall W. Fordyce, Scott McCallister, Michael D. Miller, and Christian Callebaut
Gilead Sciences, Inc., Foster City, CA
*Virologic outcome using FDA snapshot algorithm and HIV-1 RNA <50 copies/mL (Week 48 window from Days 294 thru 377); †Excludes patients without resistance development who resuppressed HIV-1 RNA to <50 copies/mL by Week 48 while maintaining study drugs;
‡Patient developed both PI (V32V/I) and NRTI (E44E/D, M184M/V) RAMs; §Patient developed both PI (L33F, M46I, I50V, V82A) and NNRTI (E138G) RAMs. APAC, Asia-Pacific; LATAM, Latin America; ND, no data.
References
1. Babusis D, et al. Mol Pharm 2013;10:459-66; 2. Birkus G, et al. Antimicrob Agents Chemother 2007;51:543-50; 3. Lee W, et al. Antimicrob Agents Chemother 2005;49:1898-906; 4. Markowitz M, et al. J Antimicrob Chemother 2014;69:1362-9; 5. Ray A, et al. Antivir Res 2016;125:63-70; 6. Ruane P, et al. J Acquir Immune Defic Syndr 2013;63:449-5; 7. Wohl D, et al. JAIDS 2016 [Epub ahead of print]; 8. Lepist EI, et al. Antimicrob Agents Chemother 2012;56:5409-13; 9. Margot N, et al. HIV Clin Trials 2016 [Epub ahead of print]; 10. Kizito H, et al. 7th International Workshop on HIV Pediatrics 2015, oral O19; 11. Porter DP, et al. CROI 2015, poster 952; 12. Huhn G, et al. IDWeek 2015, oral 726; 13. Mills A, et al. Lancet Infect Dis 2015;16:43-52; 14. Pozniak A, et al. J Acquir Immune Defic Syndr 2015 Nov 30 [Epub ahead of print]; 15. Gallant J, et al. 8th IAS 2015, poster WELBPE13; 16. Wensing AM, et al. Top Antivir Med 2015;23:132-41.
|
| |
|
|
|
|
|
